Amir Barsoum

Founder & Managing Partner InVitro Capital

Last Reviewed: September 19, 2026

Executive Summary

Amir Barsoum built the largest digital health platform in the Middle East and Africa and then did the thing very few regional founders get to do: he sold it and started again from a position of capital rather than need. Vezeeta, which he founded in Cairo in 2012, grew to serve roughly 30 million patients a year across five countries with more than a thousand staff, raising over $73 million along the way, before being acquired by a private equity firm. He remains its chairman. His executive attention has since moved to InVitro Capital, a California holding company he founded after the exit, which acquires and scales AI businesses in healthcare and adjacent service industries and has passed 170 people across five international locations while running profitably. The shape of his career is coherent rather than opportunistic — a pharmaceutical sciences degree, then McKinsey, then M&A and strategy for AstraZeneca across EMEA, then a healthcare company of his own, then a vehicle for building several at once.

Career Highlights

• Founded Vezeeta in 2012 and led it as chief executive, reaching around 30 million patients a year across five countries with over 1,000 staff.
• Raised more than $73 million for Vezeeta, including a $40 million Series D led by Gulf Capital in February 2020.
• Exited through Vezeeta’s acquisition by a private equity firm and continues as the company’s chairman.
• Founded InVitro Capital after the exit and grew it past 170 professionals across five international locations in three years, at a profit.
• Established a family office in Los Angeles between the two ventures.
• Earlier led M&A and strategy for AstraZeneca in EMEA, having begun his career at McKinsey & Company advising Fortune 500 clients.
• Named to a Fortune 40 Under 40 list of global health leaders.
• Sits on boards including Endeavor Egypt, the United Nations Global Compact and a Bloomberg New Economy health council.

Professional Journey

Barsoum trained in pharmaceutical sciences at Ain Shams University in Cairo and took an MBA at the American University in Cairo in 2008, later adding study at MIT. His first career was in advisory and corporate strategy rather than in operations: he started at McKinsey & Company working with Fortune 500 clients, then moved inside the industry his degree had pointed at, leading mergers, acquisitions and strategy for AstraZeneca across Europe, the Middle East and Africa. That is an unusually good preparation for what came next, because it meant he understood both how healthcare money moves at corporate scale and how badly the patient-facing end of the system functioned in his own market.

Vezeeta began in 2012 with a different product from the one that worked. The original idea was to sell software to individual clinics to automate doctors’ operations — a supply-side play, and one that ran straight into the adoption problem that defeats most clinical software: busy practices with no IT function do not change their workflow for a startup. Barsoum pivoted to the demand side, rebuilding the company as a patient-facing booking platform. That inversion is the single most important decision in the company’s history. Patients had an acute, repeated, unmet need — finding a doctor, knowing the price, getting an appointment without a phone call — and once patients arrived in volume, the doctors came for the demand rather than for the software.

From booking, the platform widened into medicine ordering, home visits and laboratory tests, becoming the default healthcare front door across several markets. It raised steadily: $40 million in a Series D led by the Abu Dhabi firm Gulf Capital in February 2020, then a further undisclosed round in October 2022 led by Gulf Capital with Sweden’s VNV Global, by which point the business had reached profitability — a rarer condition in MEA consumer technology than the headline funding numbers suggest. Total capital raised passed $73 million. Barsoum also pushed the company at the affordability problem directly with Vezeeta Shamel, which added payment gateways and instalment plans so patients could spread the cost of care rather than forgo it, a product decision that only makes sense if you take seriously that price, not availability, is the binding constraint for most of the population.

The exit came through acquisition by a private equity firm. Barsoum stepped out of the chief executive’s role and took the chairmanship, which is the conventional structure for a founder whose company has passed to institutional control and whose continued association still carries weight with doctors, regulators and staff. He then relocated to California — Orange County, with a family office established in Los Angeles — and spent a period as an investor rather than an operator.

InVitro Capital is what he built out of that. It is structured as a holding company rather than a fund: it acquires and scales businesses, principally applying AI to industries that have resisted software, with senior healthcare and home services among the stated targets. The model is a venture builder, meaning it originates and operates companies rather than backing other people’s, and Barsoum runs it as founder and managing partner. Within three years it had grown past 170 professionals across five international locations and was profitable — AUC’s own profile of him puts the headcount higher still and describes plans to take the Egyptian office alone to a thousand people by the end of 2026, which, whichever figure is current, indicates he has kept Egypt central to the operation rather than treating the move to California as a departure. Alongside this he holds board positions at Endeavor Egypt, the United Nations Global Compact and a Bloomberg New Economy health council, and has been named to a Fortune 40 Under 40 list of global health leaders.

Education

Ain Shams University

Bachelor’s, Pharmaceutical Sciences

American University in Cairo

MBA, 2008

MIT Sloan School of Management

MBA

Sources conflict on the MIT credential. InVitro Capital’s own biography states an MBA from MIT Sloan; the American University in Cairo’s alumni publication instead records the AUC MBA as his MBA and describes the MIT study as an executive degree. Both institutions are recorded because both are asserted by sources with direct knowledge, but the exact nature of the MIT qualification is unconfirmed.